{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T13:21:02Z","timestamp":1770988862855,"version":"3.50.1"},"reference-count":23,"publisher":"FapUNIFESP (SciELO)","issue":"6","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"am","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Braz J Med Biol Res"],"DOI":"10.1590\/1414-431x20165128","type":"journal-article","created":{"date-parts":[[2016,5,25]],"date-time":"2016-05-25T11:40:52Z","timestamp":1464176452000},"source":"Crossref","is-referenced-by-count":4,"title":["Pharmacovigilance of patients with multiple myeloma being treated with bortezomib and\/or thalidomide"],"prefix":"10.1590","volume":"49","author":[{"given":"T.B.M.","family":"Castro","sequence":"first","affiliation":[{"name":"Universidade Federal de Juiz de Fora, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.E.","family":"Hallack Neto","sequence":"additional","affiliation":[{"name":"Universidade Federal de Juiz de Fora, Brasil; Universidade Federal de Juiz de Fora, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Atalla","sequence":"additional","affiliation":[{"name":"Universidade Federal de Juiz de Fora, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.C.","family":"Ribeiro","sequence":"additional","affiliation":[{"name":"Universidade Federal de Juiz de Fora, Brasil"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"530","published-online":{"date-parts":[[2016]]},"reference":[{"key":"ref1","series-title":"Farmac\u00eauticos em oncologia: uma nova realidade","author":"Almeida JRC","year":"2010","edition":"2nd edn"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1182\/blood-2007-10-116129","article-title":"Improved survival in multiple myeloma and the impact of novel therapies","volume":"111","author":"Kumar SK","year":"2008","journal-title":"Blood"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1182\/asheducation.V2012.1.342.3798324","article-title":"How to use new biology to guide therapy in multiple myeloma","volume":"2012","author":"Morgan GJ","year":"2012","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"5334","DOI":"10.1200\/JCO.2005.03.723","article-title":"Thalidomide downregulates angiogenic genes in bone marrow endothelial cells of patients with active multiple myeloma","volume":"23","author":"Vacca A","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"53","DOI":"10.4137\/CMO.S7764","article-title":"Efficacy of bortezomib as first-line treatment for patients with multiple myeloma","volume":"7","author":"Painuly U","year":"2013","journal-title":"Clin Med Insights Oncol"},{"key":"ref6","series-title":"Efeitos adversos no tratamento quimioter\u00e1pico: uma vis\u00e3o para enfermeiros e farmac\u00eauticos","author":"Shimada CS","year":"2009"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"63","DOI":"10.32635\/2176-9745.RBC.2002v48n1.2266","article-title":"Crit\u00e9rios comuns de toxicidade do Instituto Nacional de C\u00e2ncer dos Estados Unidos","volume":"48","author":"Saad ED","year":"2002","journal-title":"Rev Bras Cancerol"},{"key":"ref8","series-title":"Farmacovigil\u00e2ncia: da teoria \u00e8 pr\u00e1tica","author":"Varallo F","year":"2013"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle RA","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","article-title":"Revised international staging system for multiple myeloma: A report from International Myeloma Working Group","volume":"33","author":"Palumbo A","year":"2015","journal-title":"J Clin Oncol"},{"key":"ref11","series-title":"Seer stat fact sheets: myeloma"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"5501","DOI":"10.1182\/blood-2010-07-298760","article-title":"Racial disparities in incidence and outcome in multiple myeloma: a population-based study","volume":"116","author":"Waxman AJ","year":"2010","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3324\/haematol.11637","article-title":"Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma","volume":"93","author":"Hungria VT","year":"2008","journal-title":"Haematologica"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.1182\/blood-2014-12-615187","article-title":"Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report","volume":"125","author":"Palumbo A","year":"2015","journal-title":"Blood"},{"key":"ref15","first-page":"136","article-title":"[Polypharmacy: interaction and adverse reactions in the use of drugs by elderly people]","volume":"63","author":"Secoli SR","year":"2010","journal-title":"Rev Bras Enferm"},{"key":"ref16","first-page":"246","article-title":"Rea\u00e7\u00f5es adversas a medicamentos em idosos: como prev\u00ea-las?","volume":"5","author":"Passarelli MCG","year":"2007","journal-title":"Einstein"},{"key":"ref17","series-title":"Alkylating agents: adverse effects and hematological complications","author":"Ferdinandi DM"},{"key":"ref18","first-page":"194","article-title":"Management of thalidomide toxicity","volume":"1","author":"Ghobrial IM","year":"2003","journal-title":"J Support Oncol"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","article-title":"Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy","volume":"27","author":"Richardson PG","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau P","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.3324\/haematol.2012.067793","article-title":"Updated survival analysis of a randomized phase III study of subcutaneous versus intravenous bortezomib in patients with relapsed multiple myeloma","volume":"97","author":"Arnulf B","year":"2012","journal-title":"Haematologica"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.gastrohep.2010.05.009","article-title":"Rectal bleeding and diarrhea caused by bortezomib-induced colitis","volume":"33","author":"Nogales Rincon O","year":"2010","journal-title":"Gastroenterol Hepatol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"4507","DOI":"10.1200\/JCO.2006.05.6689","article-title":"Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring","volume":"24","author":"Mileshkin L","year":"2006","journal-title":"J Clin Oncol"}],"container-title":["Brazilian Journal of Medical and Biological Research"],"original-title":[],"link":[{"URL":"http:\/\/www.scielo.br\/pdf\/bjmbr\/v49n6\/1414-431X-bjmbr-1414-431X20165128.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T12:13:01Z","timestamp":1656591181000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.scielo.br\/scielo.php?script=sci_arttext&pid=S0100-879X2016000600705&tlng=en"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016]]},"references-count":23,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2016]]}},"alternative-id":["S0100-879X2016000600705"],"URL":"https:\/\/doi.org\/10.1590\/1414-431x20165128","relation":{},"ISSN":["1414-431X","0100-879X"],"issn-type":[{"value":"1414-431X","type":"electronic"},{"value":"0100-879X","type":"print"}],"subject":[],"published":{"date-parts":[[2016]]},"article-number":"e5128"}}